Maynard Um
-
-
-
-
-
-
-
BofA Securities Upgrades Moderna (MRNA) to Neutral
-
-
-
-
-
-
-
Moderna shares soar on melanoma drug trial success
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
-
-
-
-
-
-
JPMorgan analysts name top short ideas for third quarter 2026
-
-
-
-
-
-
-
Moderna (MRNA) PT Raised to $77 at Piper Sandler
-
-
-
-
-
-
-
Moderna Wins Fda Panel Backing For Mrna Flu Vaccine
-
-
-
-
-
-
-
Moderna (MRNA) sees strong intraday gains
-
439,152 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

